About Recipharm Pharmaservices Private Limited
Data last updated:
Recipharm Pharmaservices Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Recipharm Lifesciences India Private Limited. It operates in the chemical products segment of the chemicals sector. It was incorporated on 30 December 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2015PTC440983. Its GSTIN is 29AAFCD5616H1ZK (Karnataka).
The company has an authorised share capital of ₹658.1 Cr and a paid-up capital of ₹18.32 Cr. It was formerly known as Dagny Pharma Private Limited. It is led by directors including Ina Quinn and Sourish Mittra.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹421.11 Cr, a decline of 3% compared to the previous year. For the same year it recorded a net profit of ₹41.05 Cr (net margin 9.7%) and EBITDA of ₹93.23 Cr (EBITDA margin 22.1%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 5% over five years.
The company has about 1,077 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Recipharm. Court records list 9 cases involving the company, including 8 filed by the company and 1 filed against it; 3 cases are pending. The company has 7 deals on record (3 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹398.47 Cr; the latest was in June 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Zydus Hospira Oncology Private Limited with revenue of ₹430.96 Cr. The company has 9 MSME Form 1 returns on record between 2021 and 2024, listing 94 overdue payments to 16 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website recipharm.com.
Company details
CIN history
Recipharm Pharmaservices has one previous CIN (Corporate Identification Number): U24230KA2015PTC084997. The current CIN is U24230MH2015PTC440983, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230MH2015PTC440983 | Current |
| U24230KA2015PTC084997 | Previous |
Contact details
Recipharm Pharmaservices Private Limited's registered office is in Mumbai, Maharashtra. Its website is recipharm.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFlat No. 502 B Wing Building No. 48, Tilak Indrayani Housing Society Tilak Nagar (W) Chembur, Mumbai, Maharashtra, India – 400089
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Recipharm Pharmaservices Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Recipharm Pharmaservices operates one associated brand: Recipharm. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical development and manufacturing services are offered contractually. | recipharm.com |
Business activity
The main business activity of Recipharm Pharmaservices is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Recipharm Pharmaservices Private Limited, buy the company report.
Financials of Recipharm Pharmaservices Private Limited
FY 2024 filings availableRecipharm Pharmaservices Private Limited reported revenue of ₹421.11 Cr (down 3% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 3% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 5%. EBITDA rose 114% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹93.23 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹41.05 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 22.1% | ||||
| Net Profit Margin | 9.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Recipharm Pharmaservices Private Limited, buy the company report.
Board of directors of Recipharm Pharmaservices Private Limited
Recipharm Pharmaservices has 3 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ina Quinn | Director | 05 Jan 2023 | 3 Years 9 Months | Current |
| Sourish Mittra | Additional Director | 22 Sep 2025 | 1 Years 1 Months | Current |
| Anita Ramgopal Borulkar | Additional Director | 03 Dec 2025 | 0 Years 10 Months | Current |
Peer comparison
Recipharm Pharmaservices Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zydus Hospira Oncology Private Limited | ₹430.96 Cr (FY 2025) | 66.0% | Village Matoda Tal Sanand, Gujarat, India | |||
| Halewood Laboratories Private Limited | ₹430.29 Cr (FY 2025) | 20.0% | Ahmedabad, Gujarat, India | |||
| Milan Laboratories (India) Private Limited | ₹429.23 Cr (FY 2024) | 42.0% | Thane, Maharashtra, India | |||
| Escientia Advanced Sciences Private Limited | ₹423.15 Cr (FY 2024) | 114.0% | Shameerpet, Telangana, India | |||
| Recipharm Pharmaservices Private Limitedthis company | ₹421.11 Cr (FY 2025) | ₹41.05 Cr | 9.7% | -3.0% | 1,077 | Mumbai, Maharashtra, India |
| Albert David Ltd | ₹420.01 Cr (FY 2024) | 18.0% | Kolkata, West Bengal, India | |||
| Aspiro Pharma Limited | ₹418.29 Cr (FY 2025) | 147.0% | Markook, Telangana, India | |||
| Scott-Edil Advance Research Laboratories & Education Limited | ₹418.23 Cr (FY 2025) | 17.0% | Chandigarh, India | |||
| Visa Drugs & Pharmaceuticals Private Limited | ₹414.04 Cr (FY 2016) | 32.0% | Kolkata, West Bengal, India | |||
| Themis Medicare Limited | ₹410.18 Cr (FY 2025) | 6.0% | Vapi, Gujarat, India |
To see the full peer comparison of Recipharm Pharmaservices Private Limited, buy the company report.
Auditor
Recipharm Pharmaservices Private Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates LLP | FY 2024 | 101049W/E300004 |
Shareholding
The shareholding of Recipharm Pharmaservices Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Recipharm Pharmaservices Private Limited, buy the company report.
Deals & funding
Recipharm Pharmaservices Private Limited has 7 deals on record (3 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹398.47 Cr; the latest was in June 2025.
Deals on record (4 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2025 | Funding round | ₹18.32 Cr | Investors: 2 individuals |
| Sep 2023 | Secondary share transfer | Undisclosed | Buyer: Recipharm Lifesciences India Private Limited Seller: Nitin Lifesciences Limited |
| Nov 2016 | Funding round | ₹223.63 Cr | Investors: Neelammegha Investments & Trading Company Private Limited , Fastspeed Vanijya LLP , 2 individuals |
| Sep 2016 | Acquisition | ₹175 Cr | Buyer: Kemwell Biopharma Private Limited |
To see the full deal history of Recipharm Pharmaservices Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Recipharm Pharmaservices Private Limited has 9 court cases on record: 8 filed by Recipharm Pharmaservices, 1 filed against it. 3 cases are pending and 6 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 0 | 0 |
| District courts | 4 | 1 | 3 |
Cases on record (5 of 9)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU RURAL, Karnataka | Court case (ECA) | Filed by the company against an individual | Pending |
| District court, BENGALURU, Karnataka | Court case (ID) | Filed against the company by Recipharm Services Workers Union, Bengaluru Rural District - 562123. | Pending |
| District court, BENGALURU RURAL, Karnataka | Civil suit | Filed by the company against an individual | Pending |
| High Court | Writ petition | Filed by the company against State of Karnataka and 3 others | Disposed |
| District court, BENGALURU, Karnataka | Criminal miscellaneous application | Filed by the company against individuals | Disposed |
To see the full case history of Recipharm Pharmaservices Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Recipharm Pharmaservices Private Limited has 9 MSME Form 1 returns on record between 2021 and 2024, listing 94 overdue payments to 16 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 16)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Kreative Actives Private Limited | |||
| Prochem Turnkey Projects Private Limited | |||
| an individual supplier | |||
| Process Engineering Retention Technique Private Limited |
To see the full MSME payment records of Recipharm Pharmaservices Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Recipharm Pharmaservices Private Limited has a workforce of 1,077 employees on its EPFO records as of Mar 21, 2024, across 1 active EPFO establishment.
GST
Recipharm Pharmaservices has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAFCD5616H1ZK | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Recipharm Pharmaservices Private Limited, buy the company report.
Recent activity
Recipharm Pharmaservices Private Limited has 13 board changes on record since 2021: 4 appointments and 9 cessations. The latest: Anita Ramgopal Borulkar was appointed as Additional Director on 03 Dec 2025.
4 earlier events are in the company report.
News
Frequently asked questions
Recipharm Pharmaservices is an active private limited company based in Mumbai, Maharashtra, India. The company works in chemical products, within the chemicals industry. It was incorporated on 30 December 2015 (11+ years old) and is registered under CIN U24230MH2015PTC440983.
Recipharm Pharmaservices has 3 current directors:
- Ina Quinn - Director
- Sourish Mittra - Additional Director
- Anita Ramgopal Borulkar - Additional Director
The latest financial statements of Recipharm Pharmaservices on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Recipharm Pharmaservices is 29AAFCD5616H1ZK, registered in Karnataka.
The CIN (Corporate Identification Number) of Recipharm Pharmaservices is U24230MH2015PTC440983. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Recipharm Pharmaservices has 9 court cases on record: 8 filed by the company and 1 filed against it. 3 are pending. Most are in the high courts.
Recipharm Pharmaservices was incorporated on 30 December 2015, making it 11+ years old. It is registered with the Registrar of Companies, Mumbai.
Recipharm Pharmaservices has 7 deals on record (3 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹398.47 Cr; the latest was in June 2025.
The peers of Recipharm Pharmaservices by revenue are Zydus Hospira Oncology Private Limited, Halewood Laboratories Private Limited, Milan Laboratories (India) Private Limited, Escientia Advanced Sciences Private Limited, Albert David Ltd and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anita Ramgopal Borulkar was appointed as Additional Director on 03 Dec 2025. Sourish Mittra was appointed as Additional Director on 22 Sep 2025. Srinivas Rao Davuluri ceased to be Additional Director on 16 Jan 2024. Recipharm Pharmaservices has 13 board changes on record in total.
Recipharm Pharmaservices has 9 MSME Form 1 returns on record between 2021 and 2024, listing 94 overdue payments to 16 micro and small suppliers. The latest return was filed on 19 Apr 2024.
Recipharm Pharmaservices can be reached through the website recipharm.com. Its registered office is in Mumbai, Maharashtra, India.